#

19-21 SEPTEMBER 2017 //

MARITIM PROARTE HOTEL, BERLIN

Cell & Gene Therapy Europe 2017

Loading
  1. PRE-CONFERENCE SUPER SESSION/ WELCOME RECEPTION

    Registration & breakfast for Phacilitate Cell & Gene Therapy Europe 2017 opens
  1. How to ensure ATMPs continue to flourish as a key growth driver across Europe?

  1. Close of session - Morning Coffee
  1. Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 0

  2. Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 1

  3. Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 2

  4. Cost effective scale up and out models to drive the commercial feasibility of ATMPs in Europe – part 3

  1. Engineered stem cells: the next great innovation wave in cell & gene therapy?

  2. Engineered stem cells: the next great innovation wave in cell & gene therapy?

  3. Engineered stem cells: the next great innovation wave in cell & gene therapy?

  4. Engineered stem cells: the next great innovation wave in cell & gene therapy?

  5. Engineered stem cells: the next great innovation wave in cell & gene therapy?

  1. Buffet lunch in the exhibition area
  1. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  2. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  3. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  4. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  5. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  6. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  7. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  8. Immuno-oncology: novel targets and innovative ways to induce a better immune response

  1. Afternoon Tea in the exhibition area
  1. Emerging cellular immunotherapy: Attacking solid tumours

  2. Emerging cellular immunotherapy: Attacking solid tumours

  3. Emerging cellular immunotherapy: Attacking solid tumours

  4. Emerging cellular immunotherapy: Attacking solid tumours

  5. Emerging cellular immunotherapy: Attacking solid tumours

  6. Emerging cellular immunotherapy: Attacking solid tumours

  7. Emerging cellular immunotherapy: Attacking solid tumours

  1. Keys to successfully navigating GMO regulations and environmental risk assessment (ERA) in Europe

  1. Close of day 1, followed by a drinks reception
  1. Registration & breakfast for Phacilitate Cell & Gene Therapy Europe 2017
  1. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  2. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  3. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  4. Finding a new way: market access strategies to ensure European patients benefit from cell, gene and immunotherapy innovation

  1. Buffet lunch in the exhibition area
  1. What tools do cell therapy manufacturers need to deliver necessary time and cost savings in QC/release testing?

  2. What tools do cell therapy manufacturers need to deliver necessary time and cost savings in QC/release testing?

  3. What tools do cell therapy manufacturers need to deliver necessary time and cost savings in QC/release testing?

  1. Viral vector bioanalytics and Quality Control: Alleviating uncertainty through regulatory insight and technical innovation

  2. Viral vector bioanalytics and Quality Control: Alleviating uncertainty through regulatory insight and technical innovation

  3. How are next-generation viral vector engineering approaches addressing long-standing targeted delivery and safety concerns?

  4. How are next-generation viral vector engineering approaches addressing long-standing targeted delivery and safety concerns?

  1. Biotech exit strategy boot camp part 2: IPO

  1. Afternoon Tea in the exhibition area
  1. A shift in mindset? Integrated, end-to-end supply chain and support system planning to unlock European ATMP market potential

  2. A shift in mindset? Integrated, end-to-end supply chain and support system planning to unlock European ATMP market potential

  1. Oncolytic viruses and cancer vaccines: what is on the horizon?

  2. Oncolytic viruses and cancer vaccines: what is on the horizon?

  3. Oncolytic viruses and cancer vaccines: what is on the horizon?

  4. Oncolytic viruses and cancer vaccines: what is on the horizon?

  5. Oncolytic viruses and cancer vaccines: what is on the horizon?

  6. Oncolytic viruses and cancer vaccines: what is on the horizon?

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad